CORRIGENDUM TO THE NOTICE OF EXTRA ORDINARY GENERAL MEETING ("EGM") OF KILITCH DRUGS INDIA LIMITED ("THE COMPANY"), SCHEDULED TO BE HELD ON MONDAY, 16TH NOVEMBER, 2026, AT 9:00 A.M. (IST) THROUGH VIDEO CONFERENCING ('VC') / OTHER AUDIO-VISUAL MEANS ('OAVM').

This Corrigendum is being issued in continuation of the Notice of Extra Ordinary General Meeting of the members of Kilitch Drugs (India) Limited ("**Company**") dated 22nd October, 2026 ("EGM Notice") scheduled to be held on, Monday, 16th November, 2026, at 9:00 A.M. (IST) Through Video Conferencing ('VC') / Other Audio-Visual Means ('OAVM').

In compliance with the applicable provisions of the Companies Act, 2013, the SEBI Listing Regulations, the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India, the Corrigendum to the EGM Notice is being sent by electronic mode only to Members to whom the original Notice of the EGM was sent, and whose e-mail addresses are registered with the Company/Depositories. Except for the changes as under, all contents of the Notice of the EGM to the Shareholders remain unchanged.

This Corrigendum is being issued on account of typographical error in the explanatory statement of Item No. 2. In para 3 of the explanatory statement of Item No. 2 of the EGM Notice, additional number of shares to be allotted has been specified as 1,66,472 equity shares instead of 1,66,471 equity shares. In order to incorporate and rectify the inadvertent error, the Company has issued a Corrigendum to the EGM Notice.

Members are therefore requested to take note that the para 3 of explanatory statement of item no. 2 of the notice of EGM dated 22nd October, 2026 pertaining to additional number of equity shares to be allotted pursuant to conversion of the entire outstanding debt including service cost shall be read and construed as the Company shall be allotted additional 1,66,471 equity shares of Kilitch Estro Biotech PLC ("**KEB**" or the "**Material Subsidiary**") in place of 1,66,472 equity shares and the para 3 of Item No. 2 of the explanatory statement shall be deemed to have been modified accordingly and read as under:

Para 3 of Item No. 2 of Explanatory Statement:

*Upon completion of the Conversion, the Company shall be allotted additional 1,66,471 equity shares of KEB, and its shareholding in KEB shall increase from 67% (sixty-seven percent) to 89.17% (Eighty Nine point One Seven percent). The equity shares to be allotted to the Company pursuant to the Conversion shall form part of the Company's entire shareholding in KEB proposed to be sold to HarmeeCare Pharmaceuticals (the "**Buyer**") under the KEB Sale, as set out under Item No. 1. Accordingly, the aggregate consideration of USD 12,855,000 (United States Dollors Twelve Million Eight Hundred and Fifty Five thousand) due to the Company under the KEB Sale shall be cumulative and shall cover the Company's existing shareholding in KEB as well as the equity shares to be acquired by the Company pursuant to the Conversion.*
This Corrigendum shall be read in conjunction with, and forms an integral part of, the EGM Notice dated 22nd October, 2026.

Except for the modification stated hereinabove, all other contents of the EGM Notice dated 22nd October, 2026 shall remain unchanged and continue to be in full force and effect.

This Corrigendum is being made available on the website of the Company at www.kilitch.com and on the websites of BSE Limited at https://www.bseindia.com/and the National Stock Exchange of India Limited https://www.nseindia.com/, in accordance with applicable laws and regulations.

By order of the Board
For **Kilitch Drugs (India) Limited**

Sd/-

Pushpa Nyoupane
Company Secretary
Place: Mumbai
Date: 12th November, 2026